In an article published in Law360 on July 22, Nelson Mullins partners John Kalas, Joe Fornadel, and associate Matthew Abney discussed the International Agency for Research on Cancer’s (IARC) recent priority list for evaluation and how to proactively create a legal strategy.

IARC, a branch of the World Health Organization, conducts evaluations of carcinogenic risks, which have historically influenced legal cases related to chemicals like asbestos, glyphosate, and benzene. The process relies on peer-reviewed data, but concerns arise over incomplete information and potential biases within IARC working groups. Critics argue that inconsistent conflict-of-interest policies could lead to skewed evaluations, impacting legal outcomes. Companies and interested parties are encouraged to monitor IARC activities, prepare for litigation, and educate regulators on the limitations of IARC’s data.

Subscribers to Law360 can read the full article here.